Mayo Clinic: Measles Vaccine Effectively Rids Woman of Blood Cancer

Friday, 16 May 2014 07:11 AM

By Clyde Hughes

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
A Minnesota woman involved in a Mayo Clinic trial is effectively cancer-free after receiving a massive dose of a measles vaccine, doctors said in a study published this week.

Stacy Erholtz, of Pequot Lakes, Minnesota, was told that an incurable form of blood cancer had spread throughout her entire body and that there were no more conventional cancer treatments that would help her, the Star Tribune reported.

As part of the Mayo Clinic trial, doctors administered a massive dose of a measles vaccine — enough for 10 million people — in late June. The medicine killed off the cancer cells and Erholtz has been cancer free since, according to the Star Tribune. Physicians involved in the study said that a second test subject also had similar results.

Urgent: Do You Approve Or Disapprove of President Obama's Job Performance? Vote Now in Urgent Poll
The trial results were published this week in the journal Mayo Clinic Proceedings.

"It's a landmark," Dr. Stephen Russell, a professor of molecular medicine who led the research at Mayo, told the Star Tribune. "We've known for a long time that we can give a virus intravenously and destroy metastatic cancer in mice. Nobody's shown that you can do that in people before."

Doctors said that the experiment gave researchers a "proof of concept" that a large, single dose of intravenous viral therapy can kill cancer by overwhelming its natural defenses.

Russell told KARE-TV that his team believes their research could ultimately change all future cancer treatments into single-shot cures.

"It's like a call to action," Russell told the television station. "It's not just good for our virus. It's good for every virus everybody's developing as a cancer therapy. We know this can happen."

Erholtz, 49, told KARE-TV that she suffered from multiple myeloma for 10 years and now has been cancer free for the past six months.

"My mindset was I didn't have any other options available, so why wouldn't I do it? I had to have failed all conventional treatment to do that trial," she said. "That actually happened last March. It was the easiest treatment by far with very few side effects. I hope it's the future of treating cancer infusion."

The Mayo Clinic is reportedly planning two new clinical trials involving more patients with the hope of getting the U.S. Food and Drug Administration to approve of viral treatments.

Urgent: Assess Your Heart Attack Risk in Minutes. Click Here.

Related Stories:

© 2014 Newsmax. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Send me more news as it happens.
Get me on The Wire
Send me more news as it happens.
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Zip Code:
Privacy: We never share your email.
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
You May Also Like

Cambodia HIV Outbreak: 100-Plus People Diagnosed; Investigation Sought

Friday, 19 Dec 2014 18:50 PM

More than 100 HIV infections in a single Cambodian village have spurred the country's prime minister to ask for an inves . . .

Slender Man Case: Two Girls Competent to Stand Trial in Stabbing

Friday, 19 Dec 2014 18:26 PM

Two girls who allegedly stabbed a 12-year-old friend over the online game Slender Man are competent to stand trial for a . . .

Kate Upton Sexiest Woman Alive; Model Apologizes to Teen Brother

Friday, 19 Dec 2014 17:52 PM

Model Kate Upton was selected as People magazine's first Sexiest Woman Alive, a month after Chris Hemsworth received the . . .

Top Stories

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

America's News Page
©  Newsmax Media, Inc.
All Rights Reserved